Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer

被引：1
|
作者：
Prager, Gerald [1 ]
Argiles, Guillem [2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Vienna, Austria
[2] Vall d Hebron Univ Hosp, VHIO, Barcelona, Spain
来源：
ESMO OPEN | 2017年 / 2卷 / 03期
关键词：
RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; PLACEBO; TRIAL; COMBINATION;
D O I：
10.1136/esmoopen-2017-000205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer
    Cremolini, Chiara
    Schirripa, Marta
    Loupakis, Fotios
    Falcone, Alfredo
    COLORECTAL CANCER, 2013, 2 (05) : 411 - 417
  • [32] US FDA approves regorafenib as a new treatment for metastatic colorectal cancer
    不详
    COLORECTAL CANCER, 2012, 1 (06) : 456 - 456
  • [33] ctDNA change predicts treatment outcome of regorafenib in metastatic colorectal cancer
    Lee, Dae-Won
    Han, Sae-Won
    Lim, Yoojoo
    Kim, Hwang-Phill
    Roh, Hanseong
    Kim, Min Jung
    Ryoo, Seung-Bum
    Park, Ji Won
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Kim, Tae-You
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
    Ebinc, Senar
    Oruc, Zeynep
    Urakci, Zuhat
    Kalkan, Ziya
    Kaplan, Muhammet Ali
    Kucukoner, Mehmet
    Isikdogan, Abdurrahman
    EURASIAN JOURNAL OF MEDICINE, 2022, 54 (03): : 229 - 234
  • [35] The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
    Yuki, S.
    Harada, K.
    Kawakami, T.
    Ogata, T.
    Hu, Q.
    Fushiki, K.
    Oshima, K.
    Kadowaki, S.
    Taniguchi, H.
    Muro, K.
    Nakanishi, R.
    Ando, K.
    Nambara, S.
    Nakamura, T.
    Kawamoto, Y.
    Komatsu, Y.
    Oki, E.
    Masuishi, T.
    Yamazaki, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S441 - S442
  • [36] Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
    Skarderud, Maria Roed
    Polk, Anne
    Vistisen, Kirsten Kjeldgaard
    Larsen, Finn Ole
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2018, 62 : 61 - 73
  • [37] Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC).
    Kidd, Michael Todd
    Wilcox, Ryan Eldredge
    Rogers, Jane
    Eng, Cathy
    Saadat, Siamak
    Lenz, Heinz-Josef
    Hubbard, Joleen Marie
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Regorafenib in the treatment of colorectal cancer
    Majithia, Neil
    Grothey, Axel
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (01) : 137 - 145
  • [39] Colorectal Cancer Regorafenib in metastatic, pretreated Tumors
    Krome, Susanne
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (06): : 530 - 530
  • [40] Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer
    Kostek, Osman
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (12): : 905 - 905
12345